Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Cagrilintide is a long acting amylin analog that regulates appetite, gastric emptying, and glucagon secretion to treat obesity and related metabolic disorders. There are 2 pathways cagrilintide works: #1 is the Amylin pathway Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the #Eloralintide vs #Cagrilintide